Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a ...
REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-concept in ACC. In this study, pharmacokinetic and pharmacodynamic analyses conirmed robust compound exposure in blood and target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results